Mr. Eric Lancelot
Manager of the Biology Research Department of GUERBET, a French company specialized in the research, development and production of contrast media for medical imaging. Roissy, France

Eric LANCELOT is also the project manager of the cardiovascular research of the Group. After his pharmacy studies, Eric LANCELOT prepared a PhD in pharmacology in Paris on the role of free radicals in cerebral ischemia and excitotoxic lesions of the brain. Then, he worked on the molecular mechanisms of brain damage in animal models of Parkinson’s and Huntington’s diseases at Massachusetts General Hospital, Boston. In 1998, he joined GUERBET as a researcher in pharmacology and pharmacokinetics. He is now in charge of the biological research team that develops in vitro and in vivo models for the screening of molecular imaging agents for MRI in the field of atherosclerosis, cancer and neurodegenerative diseases such as Alzheimer’s disease, multiple sclerosis and stroke. Since the end of 2005, he has been the coordinator of the collaborative project ATHIM (atherothrombosis molecular imaging) which is sponsored by the Medicen Pole of Competitivity. This project gathers academic and industrial partners for the synthesis, screening and selection of targeted contrast agents for vulnerable atherosclerotic plaque detection by MRI..